

Organized by:



In collaboration with:



Under the auspices of:



# MELANOMA bridge 2022

Naples, Italy  
December 1<sup>st</sup> - 3<sup>rd</sup>, 2022  
Royal Continental Hotel

# 2022

# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING AGENCY:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific program
- congress bags (badge, notepad, pen)
- coffee breaks and lunches from Dec 1<sup>st</sup> – Dec 3<sup>rd</sup>

# GENERAL INFORMATION

## CONGRESS VENUE:


Royal Continental Hotel

Via Partenope, 38/44

80121 - Naples

+39 081 245 2068

<http://www.royalgroup.it/royalcontinental/it>



AIRPORT

RAILWAY  
STATION

CONGRESS  
VENUE

# SCIENTIFIC RATIONAL

---

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the "Great Debate" sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma and, based on the increasing success of "Melanoma Bridge" events over the years since 2011, a panel of international faculty will join the congress that will be held in Naples in December 2022.

# SCIENTIFIC PROGRAM

Thursday, Dec 1<sup>st</sup>, 2022 | AUDITORIUM



06:00 pm Registration\*\*

## **MELANOMA BRIDGE OPENING SESSION\*\***

*Chairpersons: Paolo A. Ascierto, Francesco Marincola\**

07:00 pm Climbing out of the trough of disillusionment in the efficacy of radiation therapy and immunotherapy combinations\*\*

**Sandra Demaria**

07:20 pm How are we going to incorporate LAG3 blockade in melanoma?\*

**Michael A. Postow**

07:40 pm Next generation adoptive cell therapies\*\*

**Francesco Marincola\***

08:00 pm AIM at Melanoma\*\*

**Samantha Guild**

08:15 pm Focus on the Patient\*\*

**Claudia Piazza Cidonio**

2022

\* Invited

\*\*Not included in the CME accredited program

# SCIENTIFIC PROGRAM

Friday, Dec 2<sup>nd</sup>, 2022 | AUDITORIUM



09:30 am	Introduction and objectives <b>Paolo A. Ascierto</b>
	<b>SESSION</b> <b>MELANOMA IS MODEL FOR CANCER RESEARCH</b> Chairpersons: <b>Giuseppe Masucci, Magdalena Thurin</b>
09:35 am	Combining 10x scRNA-seq and 100 plex mIF: too much data or complimentary technologies to examine what works <b>Bernard A. Fox</b>
09:50 am	Can we predict response and toxicity to ICI with a single approach? <b>Iman Osman</b>
10:05 am	Survivorship, challenges in the immune checkpoint inhibitor era <b>Marc S. Ernstoff</b>
10:20 am	Immunotherapy of uveal melanoma <b>Soldano Ferrone</b>
10:35 am	Neoadjuvant trial design and clinical update in melanoma <b>Alexander Menzies</b>
10:50 pm	Discussion
11:05 am	Deciphering mechanisms of response and resistance to Treg depletion to inform new rational combinations <b>Sergio Quezada</b>
11:20 am	Dysbiosis in melanoma: how to score it? <b>Laurence Zitvogel</b>
11:35 am	The MD Anderson Melanoma Moon Shot: a model for high-risk, high-reward research <b>Jeffrey E. Gershenwald</b>
11:50 am	Loco-regional treatments for melanoma <b>Corrado Caracò</b>
12:05 pm	Discussion
12:20 pm	<b>LECTURE - Adjuvant Targeted Therapies: which goals achieved and which challenges are still open?</b> <b>Paolo A. Ascierto</b>
12:50 pm	Lunch**

# SCIENTIFIC PROGRAM

Friday, Dec 2<sup>nd</sup>, 2022 | AUDITORIUM



01:50 pm **SYMPOSIUM - The expanding landscape of adjuvant therapies in melanoma**

*Chairperson:* **Paolo A. Ascierto**  
**Paolo A. Ascierto, Claus Garbe\***

## SESSION

### LESS IS MORE: CRITICAL ISSUES IN CLINICAL PRACTICE

*Chairpersons:* **Alexander M. Eggermont, Jeffrey A. Sosman**

02:40 pm Less is more with Immunoscore  
**Jerome Galon**

02:55 pm Less is more in combination therapies  
**Olivier Michielin**

03:10 pm Role of adrenergic blockade in the immunotherapy efficacy  
**Igor Puzanov**

03:25 pm Genomics of therapy-resistant melanoma and translational opportunities  
**Roger S. Lo**

03:40 pm Trials to decrease toxicity and augment the benefit of combination checkpoint inhibition  
**Jeffrey S. Weber**

03:55 pm The role of neoantigen landscape in metastatic cancer patient response to pembrolizumab  
**Michelle Krogsgaard**

04:10 pm Discussion

04:40 pm *Coffee break\*\**

04:55 pm **LECTURE - Vaccination against Immunosuppressive Cell Populations in**

**Advanced Melanoma Patients**  
**Alexander M. Eggermont**

## GREAT DEBATE SESSION

*Chairpersons:* **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori**

05:15 pm LAG3 VS IPI sequencing  
**Hussein A. Tawbi, Omid Hamid**

05:45 pm Discussion

05:55 pm Is anti-PD1 still acceptable as comparator arm? Yes or no  
**Michael B. Atkins\*, Jeffrey A. Sosman**

*\*Invited*

*\*\*Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

Saturday, Dec 3<sup>rd</sup>, 2022 | AUDITORIUM



06:25 pm Discussion

## **GREAT DEBATE SESSION**

*Chairpersons:* **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**

09:30 am Adjuvant VS neoadjuvant approach for resectable stage III/IV  
**Axel Hauschild, Christian Blank**

10:00 am Discussion

10:10 am Stage II adjuvant: is there space for locoregional approaches? Yes or No  
**Jason J. Luke, Janice M. Mehnert**

10:40 am Discussion

10:50 am Any role for surgery?  
**Alexander M. Eggermont, Jean-Jacques Grob**

11:20 am Discussion

11:30 am **SYMPOSIUM - New and futures immunotherapy combinations for the treatment of patients with metastatic melanoma**

*Chairperson:* **Paolo A. Ascierto**  
**Paolo A. Ascierto, Jeffrey S. Weber**

12:20 pm *Coffee break\*\**

12:30 am **SYMPOSIUM - Decision making in the BRAF mutant metastatic melanoma: whatever we learn for clinical practice**

*Chairperson:* **Paolo A. Ascierto**  
**Paolo A. Ascierto, Reinhard Dummer**

01:20 pm *Lunch\*\**

## **SESSION EMERGENT STRATEGIES**

*Chairpersons:* **Nicola Normanno, Giuseppe Palmieri**

02:15 pm The future of non-melanoma skin cancers  
**Paolo A. Ascierto**

02:30 pm Identification of high-risk melanoma patients with gene expression profiling assays  
**Claus Garbe**

02:45 pm Melanoma induced metabolically deranged CD8+ T cells are associated with immunotherapy resistance  
**Brian R. Gastman**

\* *Invited*

\*\*Not included in the CME accredited program



# SCIENTIFIC PROGRAM

Saturday, Dec 3<sup>rd</sup>, 2022 | AUDITORIUM



- 03:00 pm Modulating the liver immune microenvironment for the treatment of uveal melanoma  
**Richard D. Carvajal**
- 03:15 pm New therapeutic targets revealed through germline genetic polymorphisms  
**Thomas F. Gajewski**
- 03:30 pm TIL Therapy in Melanoma: the future is now  
**Allison Betof-Warner**
- 03:45 pm Preliminary immunological monitoring of first-in-human immunotherapy-trio of multivalent autophagosome vaccine, anti-GITR and anti-PD-1  
**Rom S. Leidner**
- 04:00 pm Dendritic cells and combinatorial adjuvants reprogram TME and lymphoid tissues for enhanced effectiveness of PD1 blockade  
**Pawel Kalinski**
- 04:15 pm Next generation strategies to target MAPK signaling in cancer  
**Poulikos I. Poulikakos**
- 04:30 pm Discussion
- 05:00 pm Putting it all together – Practical Considerations for Monday Clinic  
**Sanjiv S. Agarwala**
- 05:15 pm Conclusions  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**

## PRESIDENCY

---



### **Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy



### **Corrado Caracò**

Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy



### **Iman Osman**

Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US



### **Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

## SCIENTIFIC BOARD

### **Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

### **Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

### **Carlo Bifulco**

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory; Director, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

### **Elizabeth M. Burton**

Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

### **Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

### **Corrado Caracò**

Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

### **Mary Dean**

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# SCIENTIFIC BOARD

---

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

**Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

**Claus Garbe**

Professor of Dermatology; President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

**Omid Hamid**

Chief of Research/Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Olivier Michielin**

Full Professor, Chair of Precision Oncology Center, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

**Iman Osman**

Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

**Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

**Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Tara Withington**

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# FACULTY

---

**Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

**Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Michael B. Atkins**

Deputy Director & Professor, Acting Chief, Division of Hematology/Oncology, Georgetown University Medical School, Washington, DC, US

**Allison Betof-Warner**

Assistant Attending Physician, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Christian Blank**

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Corrado Caracò**

Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Richard D. Carvajal**

Director of Experimental Therapeutics, Director of the Melanoma Service, Columbia University Medical Center, New York, NY, US

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

**Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

**Alexander M.M. Eggermont**

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, The Netherlands

**Marc S. Ernstoff**

Branch Chief, ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Cancer Therapy & Diagnosis Division, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Soldano Ferrone**

Professor in Residence, Department of Surgery, Harvard Medical School; Immunologist, Department of Surgery, Massachusetts General Hospital, Boston, MA, US

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Thomas F. Gajewski**

Professor of Medicine, Professor of Ben May Department of Cancer Research, Professor of Comprehensive Cancer Research Center, The University of Chicago Medical Center, Chicago, IL, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

**Claus Garbe**

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

# FACULTY

---

**Brian R. Gastman**

Professor, Department of Surgery, School of Medicine, Member of Immune Oncology Program, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, US

**Jeffrey E. Gershenwald**

Professor of Cancer Biology, Departments of Surgical Oncology and Cancer Biology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Houston, TX, US

**Jean-Jacques Grob**

Service de Dermatologie et Cancérologie Cutanée Hôpital de la Timone, Aix-Marseille Université Marseille, France

**Samantha Guild**

President AIM at Melanoma Richmond, CA, US

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Axel Hauschild**

Professor of Dermatology, Department of Dermatology, University of Kiel, Kiel, Germany

**Pawel Kalinski**

SVP, Team Science, Chair, Department of Immunology, Professor of Oncology & Chief, Translational Immuno-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Michelle Krogsgaard**

Associate Professor of Pathology, Co-leader of Tumor Immunology Program, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, US

**Rom S. Leidner**

Medical Director Head & Neck Cancer Program, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center Portland, OR, US

**Roger S. Lo**

Professor of Medicine/Dermatology, Associate Chief of Dermatology, Director of the Dermatology STAR Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, US

**Jason J. Luke**

Director, Immunotherapy and Drug Development Center, Associate Professor of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, US

**Francesco Marincola**

Senior Vice President, Global Head of Cell Therapy Research, Kite Pharma, Santa Monica, CA, US

**Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Janice M. Mehnert**

Professor of Medicine, Associate Director for Clinical Research, Laura and Isaac Perlmutter Cancer Center, Director, Melanoma and Cutaneous Medical Oncology, NYU Grossman School of Medicine, New York, NY, US

**Alexander Menzies**

Medical Oncologist, Associate Professor of Melanoma Medical Oncology, The University of Sydney; Faculty Member, Melanoma Institute Australia; Chair, Department of Cancer Medicine, Mater Hospital; Chair, Melanoma and Skin Cancer Group, Clinical Oncology Society of Australia, Sydney, Australia

**Olivier Michielin**

Full Professor, Chair of Precision Oncology Center, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

# FACULTY

---

**Nicola Normanno**

Cell Biology and Biotherapy Unit, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Iman Osman**

Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

**Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head,

**Claudia Piazza Cidonio**

Co-Founder, Melanoma Italia Onlus, Rome, Italy

**Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Poulikos I. Poulidakos**

Associate Professor, Department of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Sergio Quezada**

Professor of Cancer Immunology and Immunotherapy, Immune Regulation & Tumour Immunotherapy Lab, CRUK Senior Cancer Research Fellow, UCL Cancer Institute, University College London, London, UK

**Jeffrey A. Sosman**

Professor of Medicine, Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, US

**Hussein A. Tawbi**

Deputy Chair and Director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, Co-Director, MD Anderson Brain Metastasis Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Alessandro Testori**

Chairman surgical subgroup, EORTC Melanoma Group, Brussels, Belgium

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Jeffrey S. Weber**

Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, US

**Laurence Zitvogel**

Group Leader of Tumour immunology and immunotherapy of cancer, Gustave Roussy Institute, National Institute of Health and Medical Research (INSERM), Villejuif, France

## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Melanoma Bridge Congress has been accredited (ID CME 327-365357) with 4,2 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease", belonging to formative technical professional objective area, for 201 participants of the following professions: medical doctors, pharmacists, biologists, nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check: required sign at the beginning and at the end of works each day);
2. Complete the evaluation form at the end of the Congress.


CME certificate will be sent at the end of the validation procedure.

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

**IT IS HIGHLY RECOMMENDED TO WEAR A FFP2 MASK TO ATTEND THE CONGRESS**